I don't see this going to bankruptcy. That's why I stay in. HB is not dumb. With 1 drug approved and another fast-tracked (and mN) this company either makes it or a buyout will occur. The question now is what price we get on a BO if this doesn't turn around. The closer we get to running out of money, the less leverage HB and co will have to get a good price.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.